UroGen Pharma (URGN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on UroGen Pharma (URGN) is Neutral.

The composite score behind that read is +0.01, weighing +0.44 of bullish evidence against -0.20 bearish.

UroGen Pharma last closed at $36.83, -0.41% on the session.

Against the IVW growth benchmark the position is -1.21% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

UroGen Pharma has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks UroGen Pharma in the 95th percentile on return on equity, where 100 is best.

UroGen Pharma is classified under Health Care / Biotechnology, with a market capitalisation of $1.81B.

StockMap tracks UroGen Pharma as the 98th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite UroGen Pharma ranks 92nd of 381 in the group, against a group median of -0.08.